The Secondary Hyperparathyroidism drugs in development market research report provides comprehensive information on the therapeutics under development for Secondary Hyperparathyroidism, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Secondary Hyperparathyroidism. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Secondary Hyperparathyroidism and features dormant and discontinued products.
GlobalData tracks 11 drugs in development for Secondary Hyperparathyroidism by 11 companies/universities/institutes. The top development phase for Secondary Hyperparathyroidism is phase i with four drugs in that stage. The Secondary Hyperparathyroidism pipeline has 11 drugs in development by companies and 0 by universities/ institutes. Some of the companies in the Secondary Hyperparathyroidism pipeline products market are: Amgen, Vifor-Fresenius Medical Care Renal Pharma and Vidasym.
The key targets in the Secondary Hyperparathyroidism pipeline products market include Calcium Sensing Receptor, Vitamin D Receptor, and Extracellular Calcium Sensing Receptor.
The key mechanisms of action in the Secondary Hyperparathyroidism pipeline product include Calcium Sensing Receptor Agonist with three drugs in Pre-Registration. The Secondary Hyperparathyroidism pipeline products include four routes of administration with the top ROA being Intravenous and three key molecule types in the Secondary Hyperparathyroidism pipeline products market including Small Molecule, and Peptide.
Secondary Hyperparathyroidism overview
Secondary hyperparathyroidism is occurs when the parathyroid glands in the neck produce too much parathyroid hormone (PTH) because calcium levels are too low. Symptoms include bone deformities, broken bones, swollen joints, and chronic kidney failure. Treatment includes calcimimetic and hormone replacement therapy.
For a complete picture of Secondary Hyperparathyroidism’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
